IP Library › Granted Patent US 12,209,127
Granted Patent B2
US 12,209,127 · App. 18/473,002 · Granted Jan 28, 2025

Antibodies to programmed cell death protein 1

Inventors: Samir Khleif (Silver Spring, MD); Mikayel Mkrtichyan (Tujunga, CA)
Assignee: AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC.
C07K16/2818A61P35/00A61K2039/505C07K2317/34C07K2317/565C07K2317/75C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,209,127
App. No.
18/473,002
Granted
Jan 28, 2025
Kind
B2
Abstract

Antibodies and antigen binding fragments thereof are provided that immunospecifically bind to PD-1 and induce or promote an immune response that activates immune cell proliferation or activity. Contrary to the existing paradigm that PD-1 exclusively promotes a suppressive immune response, the disclosed antibodies and antigen binding fragments thereof, immunospecifically bind to PD-1 and cause an activating signal to be delivered to the immune cell that activates the immune cell rather than suppressing the immune cell. In one embodiment, the disclosed antibodies and antigen binding fragments thereof specifically bind to PD-1 expressed on immune cells. The binding of the disclosed antibodies and antigen binding fragments thereof to PD-1 on immune cells causes an activating signal to be transmitted into the immune cell, for example a signal that enhances or promotes cytokine production and/or activation of immune cell proliferation.

Claims (21)

1. A nucleic acid that encodes for an antibody or an antigen-binding fragment thereof that immunospecifically binds to PD-1, wherein the antibody or the antigen-binding fragment thereof comprises three heavy chain CDRs (HCDR1, HCDR2, and HCDR3) contained within the heavy chain variable region (HCVR) sequence of SEQ ID NO:27 or 28; and three light chain CDRs (LCDR1, LCDR2, LCDR3) contained within the light chain variable region (LCVR) sequence of SEQ ID NO:33 or 34.

2. The nucleic acid of claim 1 , wherein the HCDR1 domain has an amino acid sequence of SEQ ID NO:29; the HCDR2 domain has an amino acid sequence of SEQ ID NO:30; the HCDR3 domain has an amino acid sequence of SEQ ID NO:31; the LCDR1 domain has an amino acid sequence of SEQ ID NO:35; the LCDR2 domain has an amino acid sequence of SEQ ID NO:36; and the LCDR3 domain has an amino acid sequence of SEQ ID NO: 37.

3. The nucleic acid of claim 1 , wherein the antibody or the antigen-binding fragment thereof comprises an amino acid sequence of the heavy chain variable region of SEQ ID NO:27 or 28, or an amino acid sequence with at least 80% sequence identity thereto.

4. The nucleic acid of claim 1 , wherein the antibody or the antigen-binding fragment thereof comprises an amino acid sequence of the light chain variable region of SEQ ID NO:33 or 34, or an amino acid sequence with at least 80% sequence identity thereto.

5. The nucleic acid of claim 1 , wherein the antibody or the antigen-binding fragment thereof comprises an amino acid sequence of the heavy chain variable region of SEQ ID NO:27 or 28, or an amino acid sequence with at least 80% sequence identity thereto; and an amino acid sequence of the light chain variable region of SEQ ID NO:33 or 34, or an amino acid sequence with at least 80% sequence identity thereto.

6. The nucleic acid of claim 1 , wherein the antibody or the antigen-binding fragment thereof comprises a heavy chain that has an amino acid sequence of SEQ ID NO:27 or 28, or an amino acid sequence with at least 80% sequence identity thereto.

7. The nucleic acid of claim 1 , wherein the antibody or the antigen-binding fragment thereof comprises a light chain that has an amino acid sequence of SEQ ID NO:33 or 34, or an amino acid sequence with at least 80% sequence identity thereto.

8. The nucleic acid of claim 1 , wherein the antibody or the antigen-binding fragment thereof comprises a heavy chain that has an amino acid sequence of SEQ ID NO:27 or 28, or an amino acid sequence with at least 80% sequence identity thereto; and a light chain that has an amino acid sequence of SEQ ID NO:33 or 34, or an amino acid sequence with at least 80% sequence identity thereto.

9. The nucleic acid of claim 1 , wherein the antibody or the antigen-binding fragment thereof comprises a heavy chain constant region.

10. The nucleic acid of claim 9 , wherein the heavy chain constant region is an IgG constant region.

11. The nucleic acid of claim 1 , wherein the antibody or the antigen-binding fragment thereof comprises a light chain constant region.

12. The nucleic acid of claim 1 , wherein the antibody or the antigen-binding fragment thereof comprises a heavy chain constant region and a light chain constant region.

13. The nucleic acid of claim 1 , wherein the antibody or the antigen-binding fragment thereof is an immunoglobulin type selected from the group consisting of IgG, IgE, IgM, IgD, IgA, and IgY.

14. The nucleic acid of claim 1 , wherein the antibody or the antigen-binding fragment thereof is an immunoglobulin class selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2.

15. The nucleic acid of claim 1 , wherein the antibody or the antigen-binding fragment thereof is an antigen-binding fragment selected from the group consisting of Fab′, F (ab′) 2, Fv, single chain (ScFv), diScFv, diabody, and tribody.

16. The nucleic acid of claim 1 , wherein the antibody or the antigen-binding fragment thereof is a whole immunoglobulin.

17. The nucleic acid of claim 1 , wherein the antibody or antigen-binding fragment thereof is human, mouse, chimeric, humanized, or monoclonal.

18. The nucleic acid of claim 1 , wherein the antibody or antigen-binding fragment thereof is bispecific, trispecific, or multispecific.

19. A cell for producing the antibody or antigen-binding fragment thereof that specifically binds to PD-1, comprising the nucleic acid of claim 1 .

20. The cell of claim 19 , wherein the nucleic acid is a vector.

21. The cell of claim 20 , wherein the vector is an expression vector.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 26, 2024
From: BOARD OF REGENTS OF THE UNIVERSITY SYSTEM OF GEORGIA BY AND ON BEHALF OF AUGUSTA UNIVERSITY
To: AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC.
Reel/Frame 069407/0401 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 19, 2024
From: BOARD OF REGENTS OF THE UNIVERSITY SYSTEM OF GEORGIA ON BEHALF OF AUGUSTA UNIVERSITY
To: AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC.
Reel/Frame 068630/0230 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 19, 2024
From: BOARD OF REGENTS OF THE UNIVERSITY SYSTEM OF GEORGIA ON BEHALF OF AUGUSTA UNIVERSITY
To: AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC.
Reel/Frame 068630/0235 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 19, 2024
From: MKRTICHYAN, MIKAYEL
To: BOARD OF REGENTS OF THE UNIVERSITY SYSTEM OF GEORGIA ON BEHALF OF AUGUSTA UNIVERSITY
Reel/Frame 068630/0243 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 26, 2023
From: MKRTICHYAN, MIKAYEL; KHLEIF, SAMIR N.
To: BOARD OF REGENTS OF THE UNIVERSITY SYSTEM OF GEORGIA BY AND ON BEHALF OF AUGUSTA UNIVERSITY
Reel/Frame 065032/0815 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 26, 2023
From: BOARD OF REGENTS OF THE UNIVERSITY SYSTEM OF GEORGIA BY AND ON BEHALF OF AUGUSTA UNIVERSITY
To: AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC.
Reel/Frame 065032/0825 →
Continuity (6)
Continuation 17210117 · Mar 23, 2021
Continuation 16645289
Provisional Application 62657323 · Apr 13, 2018
Provisional Application 62624843 · Feb 1, 2018
Provisional Application 62555156 · Sep 7, 2017
Related Publication 20240076379A1 · Mar 7, 2024
References Cited (217)
US 4444887A · Hoffmann · 1984 [cited by applicant]
US 4716111A · Osband et al. · 1987 [cited by applicant]
US 4816397A · Boss et al. · 1989 [cited by applicant]
US 4816567A · Cabilly et al. · 1989 [cited by applicant]
US 5013556A · Woodle et al. · 1991 [cited by applicant]
US 5190929A · Borch et al. · 1993 [cited by applicant]
US 5225539A · Winter · 1993 [cited by applicant]
US 5413923A · Kucherlapati et al. · 1995 [cited by applicant]
US 5530101A · Queen et al. · 1996 [cited by applicant]
US 5545806A · Lonberg et al. · 1996 [cited by applicant]
US 5565332A · Hoogenboom et al. · 1996 [cited by applicant]
US 5569825A · Lonberg et al. · 1996 [cited by applicant]
US 5585089A · Queen et al. · 1996 [cited by applicant]
US 5624821A · Winter et al. · 1997 [cited by applicant]
US 5625126A · Lonberg et al. · 1997 [cited by applicant]
US 5633425A · Lonberg et al. · 1997 [cited by applicant]
US 5661016A · Lonberg et al. · 1997 [cited by applicant]
US 5693761A · Queen et al. · 1997 [cited by applicant]
US 5693762A · Queen et al. · 1997 [cited by applicant]
US 5766886A · Studnicka et al. · 1998 [cited by applicant]
US 5807715A · Morrison et al. · 1998 [cited by applicant]
US 5814318A · Lonberg et al. · 1998 [cited by applicant]
US 5916771A · Hori et al. · 1999 [cited by applicant]
US 5939598A · Kucherlapati et al. · 1999 [cited by applicant]
US 6005079A · Casterman et al. · 1999 [cited by applicant]
US 6180370B1 · Queen et al. · 2001 [cited by applicant]
US 6194551B1 · Idusogie et al. · 2001 [cited by applicant]
US 6311415B1 · Lind · 2001 [cited by applicant]
US 6350861B1 · Co et al. · 2002 [cited by applicant]
US 6407213B1 · Carter et al. · 2002 [cited by applicant]
US 7052694B2 · Pease et al. · 2006 [cited by applicant]
US 7332582B2 · Hardy et al. · 2008 [cited by applicant]
US 7390888B2 · Pease et al. · 2008 [cited by applicant]
US 7411051B2 · Rosen et al. · 2008 [cited by applicant]
US 7488802B2 · Collins et al. · 2009 [cited by applicant]
US 7521051B2 · Collins et al. · 2009 [cited by applicant]
US 7524498B2 · Hardy et al. · 2009 [cited by applicant]
US 7563869B2 · Honjo et al. · 2009 [cited by applicant]
US 7795494B2 · Ghayur · 2010 [cited by applicant]
US 7981416B2 · Hardy et al. · 2011 [cited by applicant]
US 8043620B2 · Qian et al. · 2011 [cited by applicant]
US 8088905B2 · Collins et al. · 2012 [cited by applicant]
US 8114845B2 · Langermann et al. · 2012 [cited by applicant]
US 8188238B2 · Pease et al. · 2012 [cited by applicant]
US 8232449B2 · Tanamachi et al. · 2012 [cited by applicant]
US 8287856B2 · Li et al. · 2012 [cited by applicant]
US 8383796B2 · Korman et al. · 2013 [cited by applicant]
US 8481687B2 · Vincent et al. · 2013 [cited by applicant]
US 8552154B2 · Freeman et al. · 2013 [cited by applicant]
US 8580247B2 · Li et al. · 2013 [cited by applicant]
US 8609089B2 · Langermann et al. · 2013 [cited by applicant]
US 8703485B2 · Buelow · 2014 [cited by applicant]
US 8709416B2 · Langermann et al. · 2014 [cited by applicant]
US 8728474B2 · Honjo et al. · 2014 [cited by applicant]
US 8779105B2 · Korman et al. · 2014 [cited by applicant]
US 8835712B2 · Tomizuka et al. · 2014 [cited by applicant]
US 9067999B1 · Honjo et al. · 2015 [cited by applicant]
US 9073994B2 · Honjo et al. · 2015 [cited by applicant]
US 9084776B2 · Korman et al. · 2015 [cited by applicant]
US 9102725B2 · Korman et al. · 2015 [cited by applicant]
US 9109025B2 · Gurney et al. · 2015 [cited by applicant]
US 9127071B2 · Yoshida et al. · 2015 [cited by applicant]
US 9205148B2 · Langermann et al. · 2015 [cited by applicant]
US 9255147B2 · Pease et al. · 2016 [cited by applicant]
US 9273135B2 · Korman et al. · 2016 [cited by applicant]
US 9358289B2 · Korman et al. · 2016 [cited by applicant]
US 9387247B2 · Korman et al. · 2016 [cited by applicant]
US 9388446B2 · Murphy et al. · 2016 [cited by applicant]
US 9393301B2 · Honjo et al. · 2016 [cited by applicant]
US 9445581B2 · Bradley et al. · 2016 [cited by applicant]
US 9492539B2 · Korman et al. · 2016 [cited by applicant]
US 9492540B2 · Korman et al. · 2016 [cited by applicant]
US 9499838B2 · Kuroiwa et al. · 2016 [cited by applicant]
US 9580507B2 · Korman et al. · 2017 [cited by applicant]
US 9686970B2 · MacDonald et al. · 2017 [cited by applicant]
US 9708635B2 · Murphy et al. · 2017 [cited by applicant]
US 9987500B2 · Papadopoulos et al. · 2018 [cited by applicant]
US 10155037B2 · Abdiche et al. · 2018 [cited by applicant]
US 10428146B2 · Qiu et al. · 2019 [cited by applicant]
US 10897541B2 · Christiano et al. · 2021 [cited by applicant]
US 11021540B2 · Khleif et al. · 2021 [cited by applicant]
US 11780921B2 · Khleif et al. · 2023 [cited by applicant]
US 20030229208A1 · Queen et al. · 2003 [cited by applicant]
US 20040049014A1 · Queen et al. · 2004 [cited by applicant]
US 20050037000A1 · Stavenhagen et al. · 2005 [cited by applicant]
US 20050064514A1 · Stavenhagen et al. · 2005 [cited by applicant]
US 20060088883A1 · Smider · 2006 [cited by applicant]
US 20070202077A1 · Brodsky et al. · 2007 [cited by applicant]
US 20090130114A1 · Qian et al. · 2009 [cited by applicant]
US 20090217401A1 · Korman et al. · 2009 [cited by applicant]
US 20100074916A1 · Nabel et al. · 2010 [cited by applicant]
US 20110256154A1 · Vincent et al. · 2011 [cited by applicant]
US 20120251556A1 · Allison et al. · 2012 [cited by applicant]
US 20130273089A1 · Getts et al. · 2013 [cited by applicant]
US 20130309250A1 · Cogswell et al. · 2013 [cited by applicant]
US 20140271629A1 · Corbit et al. · 2014 [cited by applicant]
US 20150203579A1 · Papadopoulos et al. · 2015 [cited by applicant]
US 20150210769A1 · Freeman · 2015 [cited by examiner]
US 20160032019A1 · Xiao · 2016 [cited by applicant]
US 20160159905A1 · Abdiche et al. · 2016 [cited by applicant]
US 20170210821A1 · Zimring · 2017 [cited by applicant]
US 20170239351A1 · Hamdy et al. · 2017 [cited by applicant]
US 20170240644A1 · Zhou et al. · 2017 [cited by applicant]
US 20200317808A1 · Afar · 2020 [cited by applicant]
US 20210032341A1 · Khleif et al. · 2021 [cited by applicant]
AU 2018330180A1 · 2020 [cited by applicant]
BR 112020004458A2 · 2020 [cited by applicant]
CA 3074647A1 · 2019 [cited by applicant]
CL 2020000576A1 · 2020 [cited by applicant]
CN 1753912A · 2006 [cited by applicant]
CN 101213297A · 2008 [cited by applicant]
CN 111133005A · 2020 [cited by applicant]
CO 2020003165A2 · 2020 [cited by applicant]
EP 0239400A2 · 1987 [cited by applicant]
EP 0519596A1 · 1992 [cited by applicant]
EP 0592106A1 · 1994 [cited by applicant]
EP 2530091A1 · 2012 [cited by applicant]
EP 3679070A1 · 2020 [cited by applicant]
IL 272911A · 2020 [cited by applicant]
JP 2011504501A · 2011 [cited by applicant]
JP 2013523166A · 2013 [cited by applicant]
JP 2014524746A · 2014 [cited by applicant]
JP 2015504419A · 2015 [cited by applicant]
JP 2016531304A · 2016 [cited by applicant]
JP 2020532991A · 2020 [cited by applicant]
KR 20200045520A · 2020 [cited by applicant]
RU 2014111999A · 2016 [cited by applicant]
WO 9109967A1 · 1991 [cited by applicant]
WO 9110741A1 · 1991 [cited by applicant]
WO 9317105A1 · 1993 [cited by applicant]
WO 9404678A1 · 1994 [cited by applicant]
WO 9425591A1 · 1994 [cited by applicant]
WO 9633735A1 · 1996 [cited by applicant]
WO 9634096A1 · 1996 [cited by applicant]
WO 9816654A1 · 1998 [cited by applicant]
WO 9824893A2 · 1998 [cited by applicant]
WO 9846645A2 · 1998 [cited by applicant]
WO 9850433A2 · 1998 [cited by applicant]
WO 9958572A1 · 1999 [cited by applicant]
WO 2007056539A2 · 2007 [cited by applicant]
WO 2008112017A2 · 2008 [cited by applicant]
WO 2010036959A2 · 2010 [cited by applicant]
WO 2011110621A1 · 2011 [cited by applicant]
WO 2013012747A1 · 2013 [cited by applicant]
WO 2015112800A1 · 2015 [cited by applicant]
WO 2015112900A1 · 2015 [cited by applicant]
WO 2016014688A2 · 2016 [cited by applicant]
WO 2016020856A2 · 2016 [cited by applicant]
WO 2016168716A1 · 2016 [cited by applicant]
WO 2019051164A1 · 2019 [cited by applicant]
Abuchowski, et al., Soluble Polymer-Enzyme Adducts, “Enzymes as Drugs” by Hocenberg and Roberts, Chapter 13, Published by Wiley-Interscience, 1981, pp. 367-383. [cited by applicant]
Angal, et al., A single amino acid substitution abolishes the heterogeneity of chimeric Mouse/human (IgG4) antibody, Mol Immunol., vol. 30, No. 1, Jan. 1993, pp. 105-108. [cited by applicant]
Ausubel, et al., Mutagenesis of Cloned DNA, Short Protocols in Molecular Biology, Chapter 8, Published by Green Publishing Associates and John Wiley & Sons, 1992, pp. 8-1-8-25. [cited by applicant]
Baca, et al., Antibody humanization using monovalent phage display, J Biol Chem., vol. 272, No. 16, Apr. 18, 1997, pp. 10678-10684. [cited by applicant]
Bass, et al., Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer, Cancer Immunol Immunother., vol. 47, No. 1, Sep. 1998, pp. 1-12. [cited by applicant]
Berger, et al., Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies, Clin Cancer Res., vol. 14, No. 10, May 15, 2008, pp. 30… [cited by applicant]
Brode, et al., Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide, Crit Rev Immunol., vol. 28, No. 2, 2008, pp. 109-126. [cited by applicant]
Bruggemann, et al., Human antibody production in transgenic animals, Arch Immunol Ther Exp (Warsz)., vol. 63, No. 2, Apr. 2015, pp. 101-108. [cited by applicant]
Butte, et al., Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses, Immunity., vol. 27, No. 1, Jul. 2007, pp. 111-122. [cited by applicant]
Caldas, et al., Design and synthesis of germline-based hemi-humanized single-chain Fv against the CD18 surface antigen, Protein Eng., vol. 13, No. 5, May 2000, pp. 353-360. [cited by applicant]
Chothia, et al., Canonical structures for the hypervariable regions of immunoglobulins, J Mol Biol., vol. 196, No. 4, Aug. 20, 1987, pp. 901-917. [cited by applicant]
Chothia, et al., Structural determinants in the sequences of immunoglobulin variable domain, J Mol Biol., vol. 278, No. 2, May 1, 1988, pp. 457-479. [cited by applicant]
Chilean Examiner's Report, received in CL 2020-000576, received on Dec. 11, 2021, 15 pages (1 page of English Translation and 14 Pages Official Copy). [cited by applicant]
Couto, et al., Anti-BA46 monoclonal antibody Mc3: humanization using a novel positional consensus and in vivo and in vitro characterization, Cancer Res., vol. 55, No. 8, Apr. 15, 1995, pp. 1717-1722. [cited by applicant]
Couto, et al., Designing human consensus antibodies with minimal positional templates, Cancer Res., vol. 55, No. 23 Suppl, Dec. 1, 1995, pp. 5973s-5977s. [cited by applicant]
Cubillos-Ruiz, et al., Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity, J Clin Invest., vol. 119, No. 8, Aug. 2009, pp. 2231-2244. [cited by applicant]
Erbe, et al., Small molecule ligands define a binding site on the immune regulatory protein B7.1, J Biol Chem., vol. 277, No. 9, Mar. 1, 2002, pp. 7363-7368. [cited by applicant]
Freeman, Gordon J., Structures of PD-1 with its ligands: sideways and dancing cheek to cheek, Proc Natl Acad Sci U S A., vol. 105, No. 30, Jul. 29, 2008, pp. 10275-10276. [cited by applicant]
Gillies, et al., High-level expression of chimeric antibodies using adapted cDNA variable region cassettes, J Immunol Methods., vol. 125, No. 1-2, Dec. 20, 1989, pp. 191-202. [cited by applicant]
Grimaldi, et al., Nivolumab plus interferon-γ in the treatment of intractable mucormycosis, Lancet Infect Dis., vol. 17, No. 1, Jan. 2017, p. 18. [cited by applicant]
Guatelli, et al., Isothermal, in vitro amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication, Proc Natl Acad Sci U S A., vol. 87, No. 5, Mar. 1990, pp. 1874-1878. [cited by applicant]
He, et al., Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer, Sci Rep., vol. 5, No. 13110, Aug. 17, 2015, 9 pages. [cited by applicant]
Hengst, et al., Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors, Cancer Res., vol. 41, No. 6, Jun. 1981, pp. 2163-2167. [cited by applicant]
Hengst, et al., Importance of timing in cyclophosphamide therapy of MOPC-315 tumor-bearing mice, Cancer Res., vol. 40, No. 7, Jul. 1, 1980, pp. 2135-2141. [cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US18/049854, mailed on Mar. 19, 2020, 10 pages. [cited by applicant]
International Search Report received for PCT Patent Application No. PCT/US2018/049854, mailed on Dec. 10, 2018, 9 pages. [cited by applicant]
Iwai, et al., Cancer immunotherapies targeting the PD-1 signaling pathway, J Biomed Sci., vol. 24, No. 1, Apr. 4, 2017, 11 pages. [cited by applicant]
Jakobovits , Aya, Production of fully human antibodies by transgenic mice, Curr Opin Biotechnol., vol. 6, No. 5, Oct. 1995, pp. 561-566. [cited by applicant]
Jakobovits, et al., From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice, Nat Biotechnol., vol. 25, No. 10, Oct. 2007, pp. 1134-1143. [cited by applicant]
Jasion, et al., Survival and digestibility of orally-administered immunoglobulin. Preparations containing IgG through the gastrointestinal tract in humans, Nutr J., vol. 14, No. 22, Mar. 7, 2015, 8 pages. [cited by applicant]
Jones, et al., Replacing the complementarity-determining regions in a human antibody with those from a mouse, Nature., vol. 321, No. 6069, 1986, pp. 522-525. [cited by applicant]
Lazar-Molnar, et al., Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2, Proc Natl Acad Sci U S A., vol. 105, No. 30, Jul. 29, 2008, pp. 10483-10488. [cited by applicant]
Li, et al., Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy, Clin Cancer Res., vol. 12, No. 22, Nov. 15, 2006, pp.… [cited by applicant]
Liang, et al., Design of new oxazaphosphorine anticancer drugs, Curr Pharm Des., vol. 13, No. 9, 2007, pp. 963-978. [cited by applicant]
Lonberg, et al., Human antibodies from transgenic mice, Int Rev Immunol., vol. 13, No. 1, 1995, pp. 65-93. [cited by applicant]
Lonberg, Nils, Human antibodies from transgenic animals, Nat Biotechnol., vol. 23, No. 9, Sep. 2005, pp. 1117-1125. [cited by applicant]
Machiels, et al., Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice, Cancer… [cited by applicant]
Mathiowitz, et al., Novel Microcapsules for delivery systems, Reactive Polymers, vol. 6, Oct. 1987, pp. 275-283. [cited by applicant]
Mathiowitz, et al., Polyanhydride microspheres as drug carriers I. Hot-melt microencapsulation, Journal of Controlled Release, vol. 5, No. 1, Jun. 1987, pp. 13-22. [cited by applicant]
Mathiowitz, et al., Polyanhydride microspheres as drug carriers. II. Microencapsulation by solvent removal, Journal of Applied Polymer Science, vol. 35, No. 3, Feb. 20, 1988, pp. 755-774. [cited by applicant]
Morea, et al., Antibody modeling: implications for engineering and design, Methods., vol. 20, No. 3, Mar. 2000, pp. 267-279. [cited by applicant]
Morrison, S L., Transfectomas provide novel chimeric antibodies, Science, vol. 229, No. 4719, Sep. 20, 1985, pp. 1202-1207. [cited by applicant]
Most, et al., Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy, Cancer Im… [cited by applicant]
Muyldermans, et al., Recognition of antigens by single-domain antibody fragments: The superfluous luxury of paired domains, Trends Biochem Sci., vol. 26, No. 4, Apr. 2001, pp. 230-235. [cited by applicant]
Notice of Allowance received for U.S. Appl. No. 16/645,289, mailed on Dec. 22, 2020. [cited by applicant]
Office Action received for European Patent Application No. 18779878.0, mailed on Aug. 20, 2021, 5 pages. [cited by applicant]
Office Action received in NC2020/0003165, issued on Jan. 14, 2022, 17 pages (8 pages of English Translation and 9 pages of Official Copy). [cited by applicant]
Padlan, Eduardo A., A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties, Mol Immunol., vol. 28, No. 4-5, 1991, pp. 489-498. [cited by applicant]
Pedersen, et al., Comparison of surface accessible residues in human and murine immunoglobulin Fv domains. Implication for humanization of murine antibodies, J Mol Biol., vol. 235, No. 3, Jan. 21, 1994, pp. 959-973. [cited by applicant]
Philippart, et al., Oral Delivery of Therapeutic Proteins and Peptides: An Overview of Current Technologies and Recommendations for Bridging from Approved Intravenous or Subcutaneous Administration to Novel Oral Regimen… [cited by applicant]
Pluckthun, A., Antibodies from [cited by applicant]
Presta, Leonard G., Antibody engineering, Current Opinion in Structural Biology., vol. 2, No. 4, Aug. 1992, pp. 593-596. [cited by applicant]
Reilly, et al., Oral delivery of antibodies. Future pharmacokinetic trends, Clin Pharmacokinet., vol. 32, No. 4, Apr. 1997, pp. 313-323. [cited by applicant]
Riechmann, et al., Reshaping human antibodies for therapy, Nature., vol. 332, No. 6162, Mar. 24, 1988, pp. 323-327. [cited by applicant]
Riechmann, et al., Single domain antibodies: comparison of camel VH and camelised human VH domains, J Immunol Methods, vol. 231, No. 1-2, Dec. 10, 1999, pp. 25-28. [cited by applicant]
Riley, James L., PD-1 signaling in primary T cells, Immunol Rev., vol. 229, No. 1, May 2009, pp. 114-125. [cited by applicant]
Roguska, et al., A comparison of two murine monoclonal antibodies humanized by CDR-grafting and variable domain resurfacing, Protein Eng., vol. 9, No. 10, Oct. 1996, pp. 895-904. [cited by applicant]
Roguska, et al., Humanization of murine monoclonal antibodies through variable domain resurfacing, Proc Natl Acad Sci U S A., vol. 91, No. 3, Feb. 1, 1994, pp. 969-973. [cited by applicant]
Sammartino, et al., Anti-GBM disease following CTLA4 blockade in a patient with metastatic melanoma , NDT Plus, vol. 3, No. 2, Apr. 2010, pp. 135-137. [cited by applicant]
Sandhu, Jasbir Singh, A rapid procedure for the humanization of monoclonal antibodies, Gene., vol. 150, No. 2, Dec. 15, 1994, pp. 409-410. [cited by applicant]
Studnicka, et al., Human-engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementarity-modulating residues, Protein Eng., vol. 7, No. 6, Jun. 1994, pp. 805-814. [cited by applicant]
Taieb, et al., Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines, J Immunol., vol. 176, No. 5, Mar. 1, 2006, pp. 2722-2729. [cited by applicant]
Tan, et al., “Superhumanized” antibodies: reduction of immunogenic potential by complementarity-determining region grafting with human germline sequences: application to an anti-CD28, J Immunol., vol. 169, No. 2, Jul. 1… [cited by applicant]
Wang, et al., In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates, Cancer Immunol Res., vol. 2, No. 9, Sep. 2014, pp. 846-856. [cited by applicant]
Weiss, R, Hot prospect for new gene amplifier, Science, vol. 254, No. 5036, Nov. 29, 1991, pp. 1292-1293. [cited by applicant]
International Search Report for PCT/US2023/061449 mailed Jul. 20, 2023. [cited by applicant]
Lee , et al., “Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy”, Nat Commun., vol. 7, No. 13354, Oct. 31, 2016, 10 pages. [cited by applicant]